Over the past two decades, there has been a significant increase in the incidence of primary liver cancer in the USA, with higher rates observed in men.
Boehringer Ingelheim inks chronic liver disease research pact with Ochre Bio
Boehringer Ingelheim is paying Ochre Bio $35 million in upfront and near-term payments to discover new treatments for chronic liver diseases like metabolic dysfunction-associated steatohepatitis.